HBA adds 10 to its board.

Share this article:
The Healthcare Businesswomen's Association (HBA) has appointed an additional 10 new members to its 25-member advisory board. Many of the new members are recipients of the HBA's annual Woman of the Year or Honorable Mentor awards.
HBA president Daria Blackwell said in a statement, "The association's advisory board works with its board of directors to address the status of women in the healthcare industry and provides strategic direction on ways the association can further the advancement of women's careers through the HBA's national and regional initiatives."
Barbara Pritchard, president-elect of the HBA, added that "because these advisory board members have seen many changes in the industry, they are in an excellent position to play an important role as mentors in the HBA's development as an organization."
New HBA advisory board members, all of whom will serve a three-year term, are: Carol Ammon, chairman and chief executive, Endo Pharmaceuticals; Judith Britz, Ph.D., chairman and chief executive, Cylex; Annie Callanan, executive vice president, Advanstar Medical Economics Healthcare Publishing Group; Teri Cox, senior managing partner, Cox Communications Partners; Ronald Dollens, president and chief executive, Guidant Corp.; James Hynd, senior vice president, commercial operations, Solvay Pharmaceuticals; Candice Lange, director, Workforce Partnering Eli Lilly; Jill Mueller, group vice president, human resources pharmaceuticals group and global pharmaceutical R&D, Abbott Laboratories; Christine Poon, worldwide chairman, medicines and nutritionals, Johnson & Johnson, and Rowena Track, vice president, global e-business, global strategic marketing, Bayer HealthCare.
Share this article:
close

Next Article in News

Email Newsletters

More in News

Meaningful use not linked to quality: study

Meaningful use not linked to quality: study

A recent study of physicians found no correlation between following EHR meaningful use requirements and providing consistently higher quality of care.

Lilly Q1 sales dip

Lilly Q1 sales dip

US sales fell 34% during the quarter, largely due to lower demand and lower prices for off-patent Cymbalta and Evista.

Gilead reaps huge HCV sales, payer fury

Gilead reaps huge HCV sales, payer fury

Sovaldi's debut has been marked by plenty of criticism from payers and lawmakers, but the hep. C drug's launch, now confirmed to be the fastest of all time, has also ...